含的抗癌药物:以目标为中心的结构-活性关系和临床管道的审查
Haeun Lee1,2, Mingi Kim1, Byungsun Jeon3,4
1Biomedical Research Division, Korea Institute of Science and Technology, Seongbuk-Gu, Seoul, 02792, Republic of Korea.
Archives of pharmacal research
|November 17, 2025
概括
化学提供了针对瘤的新型抗癌剂. 这些基药物为下一代癌症治疗提供了更好的选择性和更少的副作用.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 在历史上在药物化学中未得到充分利用,现在因其独特的特性而得到认可,使其能够进行创新的治疗设计.
- 含药物如博尔特佐米布 (Bortezomib) 的成功增加了对基化合物的兴趣,以准与瘤有关的蛋白质.
研究的目的:
- 提供首个含抗癌剂的以目标为中心的合成.
- 整合酶和受体点的结构-活性关系,结合方式和临床状态.
- 突出在克服抗性和瘤学选择性障碍方面的作用.
主要方法:
- 关于含抗癌剂的现有文献的综述.
- 分析以目标为中心的合成策略.
- 整合结构-活动关系和绑定模式可视化.
- 对各种基化合物的临床管道状况的评估.
主要成果:
- 可以实现可逆的共价抑制,前期药物激活和生物异构体替代.
- 基化合物显示出克服耐药性和增强选择性的潜力.
- 将治疗药物分为向酶和向受体的药物,并讨论机制和进展.
结论:
- 基化学是开发下一代瘤疗法的强大工具.
- 与传统药物相比,含的治疗药物具有更好的特异性和更少的副作用.
- 基化合物的进一步开发对癌症治疗具有重大前景.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K

